clinical trial · NCT04102098
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Carcinoma, HepatocellularAtezolizumabBevacizumab
brief summary
This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.
started
Dec 31, 2019
primary completion
Oct 21, 2022
completion
May 15, 2026
last updated
Jun 18, 2026
official title
A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol